ZEB1 and melanoma: Data from cell lines and patients indicate that a subset of mutated BRAF melanomas with high levels of ZEB1 expression may be intrinsically insensitive to BRAFi and MEKi, suggesting that melanoma patients with high levels of ZEB1 expression may not benefit from MAPKi treatment.